Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FXFM244 in Impetigo
NCT01171326Phase 2Completed
- Sponsor
- Vyne Therapeutics
- Start
- Aug 2010
- Primary completion
- Mar 2012
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zilxi in impetigo (2 arms), sponsored by Vyne Therapeutics. Primary endpoint: Decrease in lesion count at 7 days. Started Aug 2010; status: completed.
02
Drugs
zilxi
03
Conditions
impetigo
Beyond the preview
Go deeper on NCT01171326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01171326.